指南与共识泌尿与男性生殖病理

ISUP共识:膀胱癌混合分级、浸润性尿路上皮癌亚型及非尿路上皮癌的分级

International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 2: Grading of Mixed Grade, Invasive Urothelial Carcinoma Including Histologic Subtypes and Divergent Differentiations, and Non-Urothelial Carcinomas.
指南 / 共识 · Am J Surg Pathol · 2023-06-29

2022年ISUP膀胱癌共识会议第2工作组针对混合分级非浸润性尿路上皮癌、浸润性尿路上皮癌(含亚型与 divergent differentiation)及纯非尿路上皮癌的分级提出循证建议。工作组未就局灶高级别成分定义及T1肿瘤分级系统达成共识,但一致推荐报告亚型与 divergent differentiation 并枚举各成分,且所有亚型与 divergent differentiation 按2004 WHO系统视为高级别。纯鳞癌与纯腺癌按分化程度分级。

要点

  • 混合分级非浸润性乳头状尿路上皮癌中局灶高级别成分的定义未达成共识。
  • T1肿瘤应使用2004 WHO还是1973 WHO系统分级未达成共识。
  • 所有亚型与 divergent differentiation 按2004 WHO系统视为高级别,但行为不应视为同质。

核心结论

  • 工作组就亚型与 divergent differentiation 的报告、枚举及按2004 WHO系统归为高级别达成共识。
  • 纯鳞癌与纯腺癌应按分化程度分级。
  • 亚型与 divergent differentiation 在行为和治療反应上不应视为同质群体。

研究设计与样本

  • 2022年ISUP膀胱癌共识会议第2工作组的循证提案与共识总结。

主要发现

  • 以低级别为主、伴局灶高级别成分的非浸润性乳头状尿路上皮癌结局介于低级别与高级别肿瘤之间。
  • 按2004 WHO分级,绝大多数固有层浸润(T1)尿路上皮癌为高级别,罕见的浸润性低级别肿瘤仅显示局限的浅表浸润。
  • 按1973 WHO分级,绝大多数T1尿路上皮癌为G2和G3,且不同分级间结局差异显著。

关键数值与推荐

  • 局灶高级别成分的定义未达成共识。
  • T1肿瘤应使用2004 WHO还是1973 WHO系统分级未达成共识。
  • 任何 distinct 亚型与 divergent differentiation 均应诊断,不设阈值 cutoff,联合形态肿瘤中应枚举各类型。
  • 所有亚型与 divergent differentiation 按2004 WHO分级系统视为高级别。

临床怎么用

  • 活检、经尿道切除和膀胱切除标本中应报告并记录亚型与 divergent differentiation 的存在及范围。
  • 联合形态肿瘤中应枚举各亚型与 divergent differentiation 类型。
  • 临床建议应考虑亚型与 divergent differentiation 在行为和治療反应上的潜在异质性。
  • 未来研究应聚焦单个亚型与 divergent differentiation,而非合并为单一临床病理组。

局限性

  • 局灶高级别成分的定义未达成共识。
  • T1肿瘤的最佳分级系统未达成共识。
  • 亚型与 divergent differentiation 不应视为同质群体,需个体化研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The 2022 International Society of Urological Pathology (ISUP) Consensus Conference on Urinary Bladder Cancer Working Group 2 was tasked to provide evidence-based proposals on the applications of grading in noninvasive urothelial carcinoma with mixed grades, invasive urothelial carcinoma including subtypes (variants) and divergent differentiations, and in pure non-urothelial carcinomas. Studies suggested that predominantly low-grade noninvasive papillary urothelial carcinoma with focal high-grade component has intermediate outcome between low- and high-grade tumors. However, no consensus was reached on how to define a focal high-grade component. By 2004 WHO grading, the vast majority of lamina propria-invasive (T1) urothelial carcinomas are high-grade, and the rare invasive low-grade tumors show only limited superficial invasion. While by 1973 WHO grading, the vast majority of T1 urothelial carcinomas are G2 and G3 and show significant differences in outcome based on tumor grade. No consensus was reached if T1 tumors should be graded either by the 2004 WHO system or by the 1973 WHO system. Because of the concern for underdiagnosis and underreporting with potential undertreatment, participants unanimously recommended that the presence of urothelial carcinoma subtypes and divergent differentiations should be reported. There was consensus that the extent of these subtypes and divergent differentiations should also be documented in biopsy, transurethral resection, and cystectomy specimens. Any distinct subtype and divergent differentiation should be diagnosed without a threshold cutoff, and each type should be enumerated in tumors with combined morphologies. The participants agreed that all subtypes and divergent differentiations should be considered high-grade according to the 2004 WHO grading system. However, participants strongly acknowledged that subtypes and divergent differentiations should not be considered as a homogenous group in terms of behavior. Thus, future studies should focus on individual subtypes and divergent differentiations rather than lumping these different entities into a single clinicopathological group. Likewise, clinical recommendations should pay attention to the potential heterogeneity of subtypes and divergent differentiations in terms of behavior and response to therapy. There was consensus that invasive pure squamous cell carcinoma and pure adenocarcinoma of the bladder should be graded according to the degree of differentiation. In conclusion, this summary of the International Society of Urological Pathology Working Group 2 proceedings addresses some of the issues on grading beyond its traditional application, including for papillary urothelial carcinomas with mixed grades and with invasive components. Reporting of subtypes and divergent differentiation is also addressed in detail, acknowledging their role in risk stratification. This report could serve as a guide for best practices and may advise future research and proposals on the prognostication of these tumors.

来源:Am J Surg Pathol,查看原文。版权归原作者所有。

引用

  1. Paner GP, Kamat A, Netto GJ, et al. International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 2: Grading of Mixed Grade, Invasive Urothelial Carcinoma Including Histologic Subtypes and Divergent Differentiations, and Non-Urothelial Carcinomas. Am J Surg Pathol. 2023. PMID: 37382156. doi:10.1097/PAS.0000000000002077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。